Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AUTX-703 in Relapsed/Refractory AML and MDS
NCT06846606Phase 1Recruiting
- Sponsor
- Auron Therapeutics
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of autx-703 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) (3 arms), sponsored by Auron Therapeutics. Primary endpoint: Incidence of Adverse Events, Dose-Limiting Toxicities, and Serious Adverse Events. Started May 2025; status: recruiting.
02
Drugs
autx-703
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)
Beyond the preview
Go deeper on NCT06846606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06846606.